Host: Mark A. Socinski, MD

Guest: Edward B. Garon, MD, MS

Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression.

This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.